Mazen Dimachkie, MD
Neurology · Houston, TXNPI 1932144573
Payments from drug & device makers
Across 491 payments — averaging $3315.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$194K
- AstraZeneca$184K
- Pfizer$183K
- UCB SA$178K
- Octapharma USA, Inc.$154K
- CSL Behring$116K
- plus $619K from 26 others
Across 62 payments — averaging $970.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$29K
- Sanofi$18K
- AstraZeneca$12K
- Spark Therapeutics, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 43 | $193,872 |
| AstraZeneca(2 entities) | 18 | $184,480 |
| Pfizer | 37 | $182,541 |
| UCB SA | 45 | $177,897 |
| Octapharma USA, Inc. | 44 | $154,116 |
| CSL Behring | 11 | $116,467 |
| Argenx US, Inc. | 62 | $116,013 |
| Amicus Therapeutics, Inc. | 20 | $104,439 |
| Catalyst Pharmaceuticals, Inc. | 33 | $79,587 |
| Amgen(2 entities) | 13 | $46,154 |
| Ares Trading SA | 27 | $43,872 |
| Janssen Research & Development, LLC | 35 | $38,469 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $38,425 |
| Spark Therapeutics, Inc. | 12 | $37,895 |
| Sanofi-aventis U.S. LLC | 4 | $27,937 |
| Alnylam Pharmaceuticals Inc. | 9 | $25,024 |
| E.r. Squibb & Sons, L.L.C. | 3 | $14,228 |
| Janssen Global Services, LLC | 5 | $9,112 |
| EMD Serono Research & Development Institute, Inc. | 1 | $7,463 |
| Shire North American Group Inc | 10 | $6,131 |
| UCB, Inc. | 4 | $6,026 |
| Sanofi US Services Inc. | 5 | $5,925 |
| Grifols Therapeutics LLC | 2 | $5,808 |
| Merck Kgaa | 2 | $2,737 |
| Merck Healthcare Kgaa | 2 | $1,875 |
| Vertex | 2 | $1,125 |
| EMD Serono, Inc. | 2 | $105 |
| Hospira, Inc. | 8 | $102 |
| Johnson & Johnson | 1 | $99 |
| Bio Products Laboratory USA, Inc. | 2 | $30 |
| AbbVie | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
How this compares
$1,627,982 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Houston
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- John LindseyHouston$3.9M
- Joseph KassHouston$3.7M
- William OndoHouston$3.1M
- Vinay PuduvalliHouston$2.5M
- Erin Furr-StimmingHouston$2.1M
- Arjun TarakadHouston$2M
- Melissa YuHouston$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.